MedTrace Logo

Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients

NCT03362073 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2021-09-28

No results posted yet for this study

Summary

To establish the role of ketamine in hospitalized terminally ill cancer patients with refractory cancer pain, using continuous intravenous infusion of ketamine

Conditions

Interventions

DRUG

Ketamine

Application of ketamine using continuous intravenous infusion method during 5 days * Ketamine 100mg/2ml + 5% Dextrose water or Normal saline 98 ml mixed fluid * Dose schedule: 0.05mg/kg/hr -\> 0.10mg/kg/hr -\> … -\> 0.5mg/kg/hr (increase dose at a rate of 0.05mg/kg/hr every 8 hours)

Sponsors & Collaborators

  • Pusan National University Yangsan Hospital

    lead OTHER

Principal Investigators

  • Kwonoh Park, MD, PhD · Pusan National University Yangsan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03362073 on ClinicalTrials.gov